About this document
Understanding ANDA Requirements by Bakhshi Abdul Rahman Khalil Ahmed is a document available to read on EtoBox.
The Abbreviated New Drug Application (ANDA) is a submission to the FDA for the approval of generic drug products, which does not require preclinical or clinical data. The application must include various components such as signed forms, bioequivalence data, labeling, and manufacturing details. The Hatch-Waxman Amendments provide a 180-day exclusivity period for the first generic applicant to challenge a patent, with different types of ANDA filings depending on patent status and infringement beliefs.
- Author
- Bakhshi Abdul Rahman Khalil Ahmed
- Language
- EN